Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694241 | 0.84 | ALDH1A1 (0.44) | GDAALDH1A1ADORA3LMNASMN1; SMN2 | |
| SCHEMBL12894751 | 0.83 | ALDH1A1 (0.32) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8888536 | 0.82 | ROCK2 (0.39) | GDAALDH1A1PTK2ABL1 | |
| SCHEMBL1271343 | 0.82 | MAP2K1 (0.35) | GDAALDH1A1PTK2ADORA3DYRK1A | |
| SCHEMBL8885922 | 0.81 | GDA (0.34) | GDAALDH1A1ADORA2ALMNA | |
| SCHEMBL18325718 | 0.79 | MAT2A (0.37) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7052872 | 0.78 | ADORA2A (0.44) | ALDH1A1ADORA3ADORA2ADYRK1ACYP1A2 | |
| SCHEMBL7063733 | 0.77 | ALDH1A1 (0.43) | ALDH1A1ADORA3CYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL18325670 | 0.77 | XDH (0.39) | ABL1LMNA | |
| SCHEMBL2852189 | 0.76 | ALDH1A1 (0.32) | ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226130-A1 | 4'-THIONUCLEOSIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-2519512-B1 | N1-ACYL- 5-FLUOROPYRIMIDINONE DERIVATIVES | ADAMA MAKHTESHIM LTD (IL) | 2019-03-20 | — | — | EP | disclosed |
| EP-2519512-B1 | N1-ACYL- 5-FLUOROPYRIMIDINONE DERIVATIVES | ADAMA MAKHTESHIM LTD (IL) | 2019-03-20 | — | — | EP | disclosed |
| US-9861652-B2 | 2′ Fluoronucleosides | EMORY UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| EP-1525209-B1 | 1'-, 2'- AND 3' -MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016203337-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MOHAN M ALAPATI (IN) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203352-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MOHAN M ALAPATI (IN) | 2016-12-22 | — | — | WO | disclosed |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | EMORY UNIVERSITY | 2016-06-09 | — | — | US | disclosed |
| US-9180138-B2 | 2′-fluoronucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-8470839-B2 | N1-acyl-5-fluoropyrimidinone derivatives | DOW AGROSCIENCES, LLC. (US) | 2013-06-25 | — | — | US | disclosed |
| EP-1058686-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6069250-A | STEREOSELECTIVE SYNTHESIS OF THE BETA (CIS) ISOMER BY GLYCOSYLATING THE BASE WITH A 2-PROTECTED HYDROXYL-4-HALO-1,3-DIOXOLANE AT A TEMPERATURE OF-10 DEGREES C.; KINETICS | BIOCHEM PHARMA INC. (CA) | 2000-05-30 | — | — | US | disclosed |
| EP-0970074-A1 | METHOD AND COMPOSITIONS FOR THE SYNTHESIS OF DIOXOLANE NUCLEOSIDES WITH $g(b)-CONFIGURATION | BIOCHEM PHARMA INC (CA) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999043691-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5922867-A | GLYCOSYLATING THE NUCLEOSIDE BASE WITH AN CHEMICAL INTERMEDIATE BELOW A TEMPERATURE OF ABOUT-10.DEGREE. C. | BIOCHEM PHARMA INC. (CA) | 1999-07-13 | — | — | US | disclosed |
| CN-1208414-A | Method and compositions for the synthesis of dioxolane nucleosides with 'beta'-configuration | IAF BIOCHEM INT (CA) | 1999-02-17 | — | — | CN | disclosed |
| WO-1997021706-A1 | METHOD AND COMPOSITIONS FOR THE SYNTHESIS OF DIOXOLANE NUCLEOSIDES WITH β-CONFIGURATION | BIOCHEM PHARMA INC. (CA) | 1997-06-19 | — | — | WO | disclosed |
| US-5597824-A | VIRICIDES | ABBOTT LABORATORIES (US) | 1997-01-28 | — | — | US | disclosed |
| US-5420276-A | Ring contraction via diazoketone intermediate, active against herpes | ABBOTT LABORATORIES (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0433898-A2 | Analogs of oxetanyl purines and pyrimidines | ABBOTT LABORATORIES (US) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226130-A1 | 4'-THIONUCLEOSIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | TYMP, MTAP, TPMT | GDA 179/4885ALDH1A1 2800/4885PTK2 4852/4885 |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | PNP, BCL3, NPC1 | GDA 616/4885ALDH1A1 3494/4885PTK2 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.